Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms.
Pasquale NiscolaValentina GianfeliciMarco GiovanniniDaniela PiccioniCarla MazzonePaolo de FabritiisPublished in: Cancers (2024)
Myelodysplastic syndromes/neoplasms (MDSs) encompass a range of hematopoietic malignancies, commonly affecting elderly individuals. Molecular alterations in the hematopoietic stem cell compartment drive disease pathogenesis. Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.
Keyphrases
- hematopoietic stem cell
- clinical trial
- end stage renal disease
- bone marrow
- ejection fraction
- machine learning
- acute myeloid leukemia
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- deep learning
- gene expression
- patient reported outcomes
- dna methylation
- young adults
- phase ii
- community dwelling
- double blind